Cargando…
Making safe sense of an anti-sense!
Bepiroversen has been developed and trialed for the cure of HBV. Yuen et al.(1) report on the safety and antiviral efficacy of this agent. We “spotlight” key findings of this study and its impact for future clinical trial design.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784792/ https://www.ncbi.nlm.nih.gov/pubmed/35106512 http://dx.doi.org/10.1016/j.xcrm.2021.100503 |
| Sumario: | Bepiroversen has been developed and trialed for the cure of HBV. Yuen et al.(1) report on the safety and antiviral efficacy of this agent. We “spotlight” key findings of this study and its impact for future clinical trial design. |
|---|